Alerts will be sent to your verified email
Verify EmailAARTIDRUGS
Aarti Drugs
|
Supriya Lifescience
|
Morepen Laboratories
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
APIs Production Capacity
|
45511.0 MTPA | n/a | n/a |
R&D as a % of Total Sales
|
1.93 % | n/a | 0.87 % |
Financials
|
|||
5 yr Average ROE
|
19.9 % | 29.47 % | 13.75 % |
5yr average Equity Multiplier
|
2.08 | 1.48 | 1.84 |
5yr Average Asset Turnover Ratio
|
1.13 | 0.74 | 1.34 |
5yr Avg Net Profit Margin
|
8.4 % | 24.83 % | 5.42 % |
Price to Book
|
3.26 | 5.3 | 2.74 |
P/E
|
23.66 | 28.13 | 26.82 |
5yr Avg Cash Conversion Cycle
|
82.62 Days | 10.2 Days | 21.38 Days |
Inventory Days
|
66.37 Days | 54.74 Days | 53.55 Days |
Days Receivable
|
113.27 Days | 55.39 Days | 63.5 Days |
Days Payable
|
95.33 Days | 115.12 Days | 98.41 Days |
5yr Average Interest Coverage Ratio
|
9.51 | 36.33 | 39.33 |
5yr Avg ROCE
|
22.85 % | 37.03 % | 15.84 % |
5yr Avg Operating Profit Margin
|
14.52 % | 34.97 % | 8.37 % |
5 yr average Debt to Equity
|
0.49 | 0.17 | 0.04 |
5yr CAGR Net Profit
|
3.93 % | 10.17 % | 23.42 % |
5yr Average Return on Assets
|
9.61 % | 18.81 % | 7.36 % |
Shareholdings
|
|||
Promoter Holding
|
55.22 % | 68.3 % | 35.65 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-4.76 % | 0.06 % | -1.09 % |
Change in Mutual Fund Holding (3 Yrs)
|
7.17 % | -2.44 % | 0.0 |
Aarti Drugs
|
Supriya Lifescience
|
Morepen Laboratories
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|